About the study: The findings from this meta-analysis support TTR gene silencing for ATTR-CM. The attenuated benefit observed for patients receiving concomitant TTR stabilizer therapy may reflect residual differences in case mix, disease duration, or magnitude of TTR suppression or a true ceiling on additional benefit of gene silencing in the setting of background TTR stabilization.
Meeting Information: ESC 2026
This paper will be presented during European Society of Cardiology Congress in Munich, Germany.
Local Embargo Time: 14:30 (2:30 P.M.) CEST.
ESC Presentation: Julian Gillmore will simultaneously present the findings during the late-breaking clinical science session on cardiac amyloidosis in Ashgabat, Hall A3.
Corresponding Author: Scott D. Solomon, MD, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115 ( ssolomon@bwh.harvard.edu ).
10.1001/jama.2026.17246
To access the embargoed study: Visit our JAMA Network Media Center at this link https://media.jamanetwork.com/
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Editor's Note: Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
JAMA
Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy